Platelets Archives - Page 5 of 14 - EMEA

This site provides INTERCEPT product information for International audiences .

Pathogen reduction of double dose platelet concentrates from pools of eight Buffy coats: product quality, safety and economic aspects

Pathogen reduction of double dose platelet concentrates from pools of eight Buffy coats: product quality, safety and economic aspects

by jaycornell | May 5, 2025

Dr. Konrad Rosskopf Dept. Transfusion Medicine University Hospital of Graz, Austria

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

by jaycornell | May 5, 2025

Prof. Dr. Florian Kron Managing Director VITIS Healthcare group

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

by jaycornell | May 5, 2025

Prof. Dr. Florian Kron Managing Director VITIS Healthcare group

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

by jaycornell | May 5, 2025

Prof. Dr. Florian Kron Managing Director VITIS Healthcare group

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

Economic aspects of introducing pathogen inactivated platelets in treatment cycle of oncology patients in Germany

by jaycornell | May 5, 2025

Prof. Dr. Florian Kron Managing Director VITIS Healthcare group

« Older Entries

Next Entries »